methylprednisolone acetate has been researched along with Myofascial Pain Syndromes in 2 studies
Methylprednisolone Acetate: Methylprednisolone derivative that is used as an anti-inflammatory agent for the treatment of ALLERGY and ALLERGIC RHINITIS; ASTHMA; and BURSITIS; and for the treatment of ADRENAL INSUFFICIENCY.
methylprednisolone acetate : An acetate ester resulting from the formal condensation of the 21-hydroxy function of 6alpha-methylprednisolone compound with acetic acid.
Myofascial Pain Syndromes: Muscular pain in numerous body regions that can be reproduced by pressure on TRIGGER POINTS, localized hardenings in skeletal muscle tissue. Pain is referred to a location distant from the trigger points. A prime example is the TEMPOROMANDIBULAR JOINT DYSFUNCTION SYNDROME.
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 1 (50.00) | 18.7374 |
| 1990's | 1 (50.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Frost, FA | 1 |
| Toft, B | 1 |
| Aaboe, T | 1 |
| Lambert, MA | 1 |
| Morton, RJ | 1 |
| Sloan, JP | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Pain With Trigger Finger Injection: A Comparison of Steroid Alone Versus Steroid/Lidocaine Mixture[NCT02421419] | Phase 4 | 26 participants (Actual) | Interventional | 2015-06-30 | Terminated (stopped due to Study closed; recruitment problems) | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
A Green classification number (0-4) is given to each subject pre-injection and at 6 weeks post-injection based on their degree of triggering. 0 = No triggering, no pain; 1 = Pre-triggering; pain, history of catching, but not demonstrable on physical examination; tenderness over the A1 pulley; 2 = Active; demonstrable catching, but the patient can actively extend the digit; 3= Passive; demonstrable catching requiring passive extension or inability to actively flex; and 4 = Contracture; demonstrable catching with a fixed flexion contracture of the PIP joint. (NCT02421419)
Timeframe: Patients are assessed pre-injection objectively by investigator and at 6 weeks post-injection subjectively via Patient Survey
| Intervention | Participants (Count of Participants) | |||||||||
|---|---|---|---|---|---|---|---|---|---|---|
| Green classification 0 (pre-injection) | Green classification 1 (pre-injection) | Green classification 2 (pre-injection) | Green classification 3 (pre-injection) | Green Classification 4 (pre-injection) | Green classification 0 (6-weeks post-injection) | Green classification 1 (6-weeks post-injection) | Green classification 2 (6-weeks post-injection) | Green classification 3 (6-weeks post-injection) | Green classification 4 (6-weeks post-injection) | |
| Corticosteroid Alone (CS) Group | 0 | 2 | 4 | 0 | 0 | 2 | 0 | 2 | 2 | 0 |
| Corticosteroid/Lidocaine (CSL) Group | 0 | 1 | 10 | 0 | 0 | 1 | 0 | 2 | 7 | 1 |
| Corticosteroid/Saline (CSS) Group | 0 | 1 | 6 | 0 | 1 | 1 | 0 | 4 | 2 | 1 |
Incidence of adverse effects (NCT02421419)
Timeframe: Patients are assessed 1 minute post-injection, 10 minutes post-injection, and at 6 week post-injection.
| Intervention | Participants (Count of Participants) | ||
|---|---|---|---|
| Adverse effects 1 minute post-injection | Adverse effects 10 minutes post-injection | Adverse effects 6 weeks post-injection | |
| Corticosteroid Alone (CS) Group | 0 | 0 | 0 |
| Corticosteroid/Lidocaine (CSL) Group | 0 | 0 | 0 |
| Corticosteroid/Saline (CSS) Group | 0 | 0 | 0 |
Patients are asked how often their finger triggers - not at all, rarely, occasionally, or frequently at time intervals indicated in the outcome measure time frame. Count of participants for each of these answers was collected. (NCT02421419)
Timeframe: Patients are assessed pre-injection (baseline), 1 minute post-injection, 10 minutes post-injection, and 6 weeks post-injection
| Intervention | Participants (Count of Participants) | ||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Triggering frequently pre-injection | Triggering not at all pre-injection | Triggering occasionally pre-injection | Triggering rarely pre-injection | Triggering not at all 1 minute post-injection | Triggering rarely 1 minute post-injection | Triggering occasionally 1 minute post-injection | Triggering frequently 1 minute post-injection | Triggering same as before 1 minute post-injection | Triggering not at all 10 minutes post-injection | Triggering rarely 10 minutes post-injection | Triggering occasionally 10 minutes post-injection | Triggering frequently 10 minutes post-injection | Triggering same as before 10 min. post-injection | Triggering not at all 6 wks post-injection | Triggering rarely 6 wks post-injection | Triggering occasionally 6 weeks post-injection | Triggering frequently 6 wks post-injection | triggering same as before 6 wks post-injection | |
| Corticosteroid Alone (CS) Group | 2 | 0 | 4 | 0 | 3 | 0 | 1 | 0 | 2 | 4 | 0 | 1 | 0 | 1 | 3 | 0 | 0 | 1 | 2 |
| Corticosteroid/Lidocaine (CSL) Group | 7 | 0 | 4 | 0 | 1 | 0 | 1 | 0 | 8 | 2 | 0 | 1 | 1 | 6 | 1 | 1 | 0 | 1 | 8 |
| Corticosteroid/Saline (CSS) Group | 5 | 2 | 1 | 0 | 3 | 0 | 0 | 0 | 5 | 4 | 0 | 0 | 0 | 4 | 1 | 0 | 0 | 2 | 5 |
Visual Analogue Pain Scale (VAS) - measurement of pain on scale of 0 (least) to 10 (worst). (NCT02421419)
Timeframe: Patients are assessed pre-injection (baseline), 1 minute post-injection, 10 minutes post-injection, at 6 weeks post-injection and also asked to recollect their pain at time of injection when seen at 6 weeks post-injection
| Intervention | units on a scale (Mean) | ||||
|---|---|---|---|---|---|
| VAS pre-injection | VAS 1 minute post-injection | VAS 10 minutes post-injection | VAS 6 weeks post-injection | VAS Recollection | |
| Corticosteroid Alone (CS) Group | 2.2 | 2.3 | 2.1 | 1.5 | 5.2 |
| Corticosteroid/Lidocaine (CSL) Group | 3.0 | 2.2 | 1.2 | 3.3 | 6.6 |
| Corticosteroid/Saline (CSS) Group | 3.9 | 4.9 | 3.3 | 4.0 | 5.9 |
2 trials available for methylprednisolone acetate and Myofascial Pain Syndromes
| Article | Year |
|---|---|
[Isotonic saline and methylprednisolone acetate in blockade treatment of myofascial pain. A clinical controlled study].
Topics: Adult; Clinical Trials as Topic; Female; Humans; Isotonic Solutions; Male; Methylprednisolone; Methy | 1984 |
Controlled study of the use of local steroid injection in the treatment of trigger finger and thumb.
Topics: Adult; Aged; Double-Blind Method; Female; Fingers; Humans; Injections; Male; Methylprednisolone; Met | 1992 |